Given that CSCs are crucial for breast cancer progression and metastasis, RHBDL2 may be a new therapeutic target for control of CD44-/CD24- cell conversion into CSCs to reduce CSC pool size and limit breast cancer progression and metastasis. This evidence concerns the gene CD44 and breast carcinoma.